Adipotide
Prohibitin-Targeting Peptide 1 (FTPP)
This peptide has not been evaluated by the FDA. It is sold as a research chemical and has no regulatory status for human use.
An experimental compound studied in animal research for fat reduction by targeting the blood supply to fat tissue. A human safety trial was started but not completed, and kidney effects remain a significant concern that has limited further development. This compound is not available as a treatment.
This entry is a cited research summary, not an established treatment reference. Dosing language is included as source context, not as medical instruction.
Adipotide has limited human evidence; signal requires confirmation.
This peptide has not been evaluated by the FDA. It is sold as a research chemical and has no regulatory status for human use.
Safety Summary
The primary and dose-limiting toxicity in primate studies was renal proximal tubule dysfunction consistent with Fanconi-like syndrome, characterized by elevated serum creatinine, proteinuria, glucosuria, and electrolyte abnormalities PMID 22072637. Effects were dose-dependent and described as partially reversible upon cessation of treatment. A later study using the CKGGRAKDC sequence as a liposomal ligand found elevated kidney uptake with ATS-targeted nanoparticles, providing mechanistic support for kidney-specific accumulation of the targeting domain PMID 31725756. Renal toxicity was consistent across all primate species tested (rhesus macaques, baboons, cynomolgus monkeys). In a related D(KLAKLAK)2-containing compound (BMTP-78), renal toxicity was similarly observed as a class effect, alongside unexpected fatal cardiac arrhythmias at higher doses that were unique to BMTP-78 and not seen with adipotide PMID 29205207. No human adverse event data has been published from NCT01262664.
Clinical check-in
If real-world use or exposure is being considered, review potential interactions, contraindications, and monitoring needs with a licensed clinician rather than relying on summary copy alone.
Cited sources
Every claim on this page links to one of the 14 sources below. Identifiers are PubMed (PMID), ClinicalTrials.gov (NCT), or DOI; click through to the source of record before acting on a claim.
- 1PMID 15133506PubMed
- 2PMID 22072637PubMed
- 3PMID 22539771PubMed
- 4PMID 22049339PubMed
- 5PMID 23521790PubMed
- 6PMID 23871959PubMed
- 7PMID 27468426PubMed
- 8PMID 31725756PubMed
- 9PMID 25342467PubMed
- 10NCT01262664ClinicalTrials.gov
- 11PMID 29205207PubMed
- 12PMID 32760294PubMed
- 13PMID 37894644PubMed
- 14PMID 40760703PubMed